U.S. markets closed

OraSure Technologies, Inc. (OSUR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.79+0.12 (+1.03%)
At close: 4:00PM EDT

OraSure Technologies, Inc.

220 East First Street
Bethlehem, PA 18015
United States
610 882 1820
http://www.orasure.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full Time Employees570

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen S. TangPres, CEO & Director1.87MN/A1961
Mr. Roberto E. CucaCFO & Principal Accounting Officer937.09kN/A1968
Mr. Jack E. JerrettSr. VP, Chief Compliance Officer, Gen. Counsel & Sec.706.79kN/A1959
Ms. Kathleen Gallagher WeberExec. VP & Bus. Unit Leader of Molecular Solutions1.12MN/A1967
Ms. Lisa NibauerExec. VP & Bus. Unit Leader of Diagnostics554.85kN/A1968
Mr. Scott GleasonSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Michele Marie MillerVP of Fin., Controller & Assistant Sec.N/AN/A1974
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

Corporate Governance

OraSure Technologies, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 4. The pillar scores are Audit: 3; Board: 2; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.